GlassScriptPhysician profile
Zev Brandel
NPI 1083658801
$3,013.85
in general payments reported to CMS, 2019-2025
28 companies · $640 in 2025
The $640 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $256 · 2020: $435 · 2021: $739 · 2022: $519 · 2023: $164 · 2024: $261 · 2025: $640.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,064.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,064.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,001.67 | 2019-2025 | Repatha, Otezla, Repatha |
| Amarin Pharma, INC. | $589.06 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $247.60 | 2019-2024 | Fasenra |
| Abbott Laboratories | $149.95 | 2025 | Freestyle Libre 3 |
| Ascendis Pharma Endocrinology INC | $125.00 | 2025 | Yorvipath |
| Sanofi-Aventis U.S. LLC | $121.61 | 2019 | |
| Allergan, INC. | $114.16 | 2020 | |
| Corcept Therapeutics | $100.24 | 2024-2025 | Korlym |
| Glaxosmithkline, LLC. | $69.68 | 2020-2022 | |
| Kowa Pharmaceuticals America, INC. | $55.07 | 2021-2024 | Livalo |
| Pfizer INC. | $52.44 | 2023 | |
| Genzyme Corporation | $51.91 | 2021-2022 | |
| Ultragenyx Pharmaceutical INC. | $38.35 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $34.03 | 2025 | Recorlev |
| Novartis Pharmaceuticals Corporation | $30.44 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $27.03 | 2024 | |
| Phadia US INC. | $25.32 | 2025 | Immunocap |
| Mylan Specialty L.P. | $20.21 | 2023 | Yupelri |
| Novo Nordisk INC | $19.77 | 2022 | |
| Renalytix Ai, INC. | $18.90 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Recordati_rare_diseases_inc. | $18.23 | 2025 | Isturisa |
| Lundbeck LLC | $16.68 | 2023 | Rexulti |
| Regeneron Healthcare Solutions, INC. | $15.40 | 2021 | |
| Alexion Pharmaceuticals, INC. | $14.91 | 2024 | Strensiq |
| Scilex Pharmaceuticals INC. | $14.89 | 2019 | |
| Vistapharm, INC. | $14.50 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.62 | 2019 | |
| Esperion Therapeutics, INC. | $13.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Zev Brandel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.